ArticleDiagnostics (Basel, Switzerland)2020
Prognostic Value of Baseline Radiomic Features of
Article in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Metabolomics approaches for the early detection and therapeutics: type 2 diabetes-induced diabetic kidney disease-a systematic review and meta-analysis.Metabolomics : Official journal of the Metabolomic Society · 2025Pooled it
- Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells.Journal of cancer research and clinical oncology · 2023Trial
- Enhanced Lymphoma Subtype Classification and Prognosis Using Machine Learning withNuclear medicine and molecular imaging · 2026Article
- A proof of concept study ofScientific reports · 2025Article
- Radiomics based onQuantitative imaging in medicine and surgery · 2025Article
- Review
- PET-based radiomic feature based on the cross-combination method for predicting the mid-term efficacy and prognosis in high-risk diffuse large B-cell lymphoma patients.Frontiers in oncology · 2024Article
- Semiquantitative 2-[Frontiers in medicine · 2024Review
- BaselineEJNMMI research · 2023Article
- Early three-month report of amniotic bladder therapy in patients with interstitial cystitis/bladder pain syndrome.International urology and nephrology · 2023Article
- Survival Prediction Using Transformer-Based Categorical Feature Representation in the Treatment of Diffuse Large B-Cell Lymphoma.Healthcare (Basel, Switzerland) · 2023Article
- Radiomics in Oncological PET Imaging: A Systematic Review-Part 2, Infradiaphragmatic Cancers, Blood Malignancies, Melanoma and Musculoskeletal Cancers.Diagnostics (Basel, Switzerland) · 2022Review
- Development and validation of nomograms by radiomic features on ultrasound imaging for predicting overall survival in patients with primary nodal diffuse large B-cell lymphoma.Frontiers in oncology · 2022Article
- Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma.International journal of biological sciences · 2022Review
- Prognostic Value of Radiomic Features ofFrontiers in oncology · 2022Article
- Diagnostic value of baselineScientific reports · 2021Article
- FDG-PET/CT in Lymphoma: Where Do We Go Now?Cancers · 2021Article
- Radiomics in radiation oncology for gynecological malignancies: a review of literature.The British journal of radiology · 2021Review
- Prognostic Value of Combing Primary Tumor and Nodal Glycolytic-Volumetric Parameters ofDiagnostics (Basel, Switzerland) · 2021Article
- Radiomic Features ofContrast media & molecular imaging · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates whether baseline
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.